Clinical outcomes of contemporary drug‐eluting stents in patients with and without diabetes mellitus: Multigroup propensity‐score analysis using data from stent‐specific, multicenter, prospective registries

Whether the diabetic status differentially affects the clinical outcomes with different drug‐eluting stents (DES) has been controversial.

[1]  R. Fattori,et al.  Polymer-free amphilimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus. , 2017, International journal of cardiology.

[2]  Samin K. Sharma,et al.  Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials. , 2017, International journal of cardiology.

[3]  P. Stella,et al.  PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent. , 2016, Interventional cardiology.

[4]  S. Bangalore,et al.  Percutaneous Coronary Intervention in Patients With Insulin-Treated and Non-Insulin-Treated Diabetes Mellitus: Secondary Analysis of the TUXEDO Trial. , 2016, JAMA cardiology.

[5]  A. Colombo,et al.  Clinical outcomes of real‐world patients treated with an amphilimus polymer‐free stent versus new generation everolimus‐eluting stents , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[6]  S. Bangalore,et al.  Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes. , 2015, The New England journal of medicine.

[7]  G. Stone,et al.  Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[8]  H. Suryapranata,et al.  First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients , 2014, Open Heart.

[9]  S. Bangalore,et al.  Outcomes With Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Patients With Diabetes Mellitus: Can Newer Generation Drug-Eluting Stents Bridge the Gap? , 2014, Circulation. Cardiovascular interventions.

[10]  I. Seong,et al.  Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. , 2014, JACC. Cardiovascular interventions.

[11]  M. Mack,et al.  Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). , 2013, Journal of the American College of Cardiology.

[12]  Lane F Burgette,et al.  A tutorial on propensity score estimation for multiple treatments using generalized boosted models , 2013, Statistics in medicine.

[13]  A. Yeung,et al.  Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program. , 2013, JACC. Cardiovascular interventions.

[14]  D. Holmes,et al.  Drug-eluting coronary-artery stents. , 2013, The New England journal of medicine.

[15]  J. Harnek,et al.  Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register. , 2012, JACC. Cardiovascular interventions.

[16]  A. Kirtane,et al.  Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials , 2012, BMJ : British Medical Journal.

[17]  J. Suh,et al.  The recanalization of chronic total occlusion leads to lumen area increase in distal reference segments in selected patients: an intravascular ultrasound study. , 2012, JACC. Cardiovascular interventions.

[18]  P. Serruys,et al.  Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.

[19]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[20]  Y. Yamori,et al.  First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the "Japanese paradox". , 2011, International journal of cardiology.

[21]  P. Serruys,et al.  Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus , 2011, Circulation.

[22]  F. Eberli,et al.  Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial , 2011, Circulation.

[23]  P. Serruys,et al.  Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial , 2011, The Lancet.

[24]  M. Jeong,et al.  Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.

[25]  B. Lagerqvist,et al.  Long-term mortality after PCI in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry. , 2010 .

[26]  K. Winters,et al.  The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects , 2010, European Journal of Clinical Pharmacology.

[27]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[28]  J. Tardif,et al.  Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. , 2007, Journal of the American College of Cardiology.

[29]  Seung‐Jung Park,et al.  Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era. , 2005, The American journal of cardiology.

[30]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[31]  G. Levine,et al.  ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions , 2011 .